12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

INCB39110: Interim Phase II data

Incyte reported interim data from an open-label, dose-escalation, U.S. Phase II trial in 87 patients aged 18 and older with intermediate or high-risk primary MF, PPV-MF or PET-MF showing that oral INCB39110 led to "meaningful improvements" in MF-related symptoms, including symptoms associated with splenomegaly. Specifically, the proportion of patients who achieved a >=50% improvement in TSS as measured by the MFSAF v3.0 electronic diary from baseline to week 12, the primary endpoint, was 22.2% at the twice-daily 100 mg INCB39110 dose, 34.9% at the twice-daily 200 mg dose...

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >